At baseline, CV disease and risk factors were managed with lipid-lowering therapy (90%), platelet aggregation inhibitors (86%), angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (74%), and beta blockers (70%)
Statistical analysis was performed using IBM SPSS Statistics, version 27.0 (IBM Corporation, Armonk, NY, USA)
In a landmark study known as the STEP (Semaglutide Treatment Effect in People with obesity) trial, participants who received semaglutide injections experienced an average weight loss of 15% of their body weight over a 68-week period, compared to just 2.4% in the placebo group (Wilding et al., 2021)
While they produce modest LDL cholesterol reductions of 2-10%, statins remain first-line therapy for patients requiring significant lipid lowering, and GLP-1 agents work best as complementary therapy alongside statins
This type of heart failure accounts for more than half of all cases in the US and is increasing in prevalence, according to Kosiborod and his co-authors